SK63499A3 - Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia - Google Patents

Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia Download PDF

Info

Publication number: SK63499A3
Authority: SK; Slovakia
Prior art keywords: plasmid; nucleic acids; encoding; ires; adenovirus
Prior art date: 1996-11-15

Application number

SK634-99A

Other languages

English (en)

Slovak (sk)

Inventor

Patrick Benoit

Nicolas Duverger

Didier Rouy

Sandrine Seguret

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-15

Filing date

1997-11-13

Publication date

2000-05-16

1997-11-13 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

2000-05-16 Publication of SK63499A3 publication Critical patent/SK63499A3/sk

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 49
230000001575 pathological effect Effects 0.000 title claims description 9
208000032928 Dyslipidaemia Diseases 0.000 title description 3
239000013612 plasmid Substances 0.000 claims abstract description 116
108090000623 proteins and genes Proteins 0.000 claims abstract description 73
150000007523 nucleic acids Chemical class 0.000 claims abstract description 65
108020004707 nucleic acids Proteins 0.000 claims abstract description 62
102000039446 nucleic acids Human genes 0.000 claims abstract description 62
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 55
241000700605 Viruses Species 0.000 claims abstract description 45
102000004190 Enzymes Human genes 0.000 claims abstract description 37
108090000790 Enzymes Proteins 0.000 claims abstract description 37
102000004169 proteins and genes Human genes 0.000 claims abstract description 36
230000002950 deficient Effects 0.000 claims abstract description 33
235000012000 cholesterol Nutrition 0.000 claims abstract description 27
230000002103 transcriptional effect Effects 0.000 claims abstract description 24
230000002441 reversible effect Effects 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 39
102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 35
108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 35
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 claims description 33
210000004027 cell Anatomy 0.000 claims description 29
230000004141 reverse cholesterol transport Effects 0.000 claims description 21
239000002299 complementary DNA Substances 0.000 claims description 16
230000010076 replication Effects 0.000 claims description 16
210000004185 liver Anatomy 0.000 claims description 14
101100379247 Salmo trutta apoa1 gene Proteins 0.000 claims description 13
230000003612 virological effect Effects 0.000 claims description 12
230000008488 polyadenylation Effects 0.000 claims description 10
210000001236 prokaryotic cell Anatomy 0.000 claims description 10
241000282414 Homo sapiens Species 0.000 claims description 9
230000037430 deletion Effects 0.000 claims description 8
238000012217 deletion Methods 0.000 claims description 8
201000001320 Atherosclerosis Diseases 0.000 claims description 7
206010021024 Hypolipidaemia Diseases 0.000 claims description 7
238000002744 homologous recombination Methods 0.000 claims description 7
230000006801 homologous recombination Effects 0.000 claims description 7
208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
102000004882 Lipase Human genes 0.000 claims description 5
108090001060 Lipase Proteins 0.000 claims description 5
239000004367 Lipase Substances 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 5
235000019421 lipase Nutrition 0.000 claims description 5
108010071619 Apolipoproteins Proteins 0.000 claims description 4
102000007592 Apolipoproteins Human genes 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
108091026890 Coding region Proteins 0.000 claims description 3
241000710188 Encephalomyocarditis virus Species 0.000 claims description 3
241000709664 Picornaviridae Species 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
241000991587 Enterovirus C Species 0.000 claims description 2
241000598171 Human adenovirus sp. Species 0.000 claims description 2
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 claims 11
108091092584 GDNA Proteins 0.000 claims 1
230000001580 bacterial effect Effects 0.000 claims 1
238000012546 transfer Methods 0.000 abstract description 13
230000000694 effects Effects 0.000 description 29
102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 22
238000000034 method Methods 0.000 description 20
239000012634 fragment Substances 0.000 description 17
239000002245 particle Substances 0.000 description 17
108020004414 DNA Proteins 0.000 description 16
108020004635 Complementary DNA Proteins 0.000 description 15
238000010804 cDNA synthesis Methods 0.000 description 15
239000000872 buffer Substances 0.000 description 13
241000588724 Escherichia coli Species 0.000 description 12
230000014509 gene expression Effects 0.000 description 11
238000010276 construction Methods 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
108010007622 LDL Lipoproteins Proteins 0.000 description 9
102000007330 LDL Lipoproteins Human genes 0.000 description 9
239000000047 product Substances 0.000 description 9
239000013598 vector Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
102000012410 DNA Ligases Human genes 0.000 description 7
108010061982 DNA Ligases Proteins 0.000 description 7
150000001840 cholesterol esters Chemical class 0.000 description 7
230000029087 digestion Effects 0.000 description 7
230000006798 recombination Effects 0.000 description 7
238000005215 recombination Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
230000002093 peripheral effect Effects 0.000 description 6
239000005720 sucrose Substances 0.000 description 6
108010059886 Apolipoprotein A-I Proteins 0.000 description 5
102000005666 Apolipoprotein A-I Human genes 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
108010073614 apolipoprotein A-IV Proteins 0.000 description 5
230000006870 function Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000003902 lesion Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229960000268 spectinomycin Drugs 0.000 description 5
UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000001890 transfection Methods 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000012761 co-transfection Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
239000013605 shuttle vector Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
230000003143 atherosclerotic effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
238000011161 development Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
-1 neurofilaments Proteins 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282465 Canis Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
241000589776 Pseudomonas putida Species 0.000 description 2
101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 2
241000589196 Sinorhizobium meliloti Species 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
206010042434 Sudden death Diseases 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
239000000463 material Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000008520 organization Effects 0.000 description 2
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
108010030416 proteoliposomes Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
229950002929 trinitrophenol Drugs 0.000 description 2
238000012795 verification Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000589155 Agrobacterium tumefaciens Species 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
238000008958 Apolipoprotein A1 Assay Methods 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000701157 Canine mastadenovirus A Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102100038909 Caveolin-2 Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
239000005149 Cholesterol Linoleate Substances 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
102100036912 Desmin Human genes 0.000 description 1
108010044052 Desmin Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000030914 Fatty Acid-Binding Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
108010046315 IDL Lipoproteins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
241001518258 Streptomyces pristinaespiralis Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
241001672648 Vieira Species 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000008272 agar Substances 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
210000002403 aortic endothelial cell Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
NAACPBBQTFFYQB-LJAITQKLSA-N cholesteryl linoleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C1 NAACPBBQTFFYQB-LJAITQKLSA-N 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
101150106284 deoR gene Proteins 0.000 description 1
210000005045 desmin Anatomy 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
108091022862 fatty acid binding Proteins 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000000497 foam cell Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
101150070420 gyrA gene Proteins 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000001227 hypertriglyceridemic effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229940049918 linoleate Drugs 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
230000008604 lipoprotein metabolism Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
239000002243 precursor Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
125000005581 pyrene group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000008719 thickening Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
108090000195 villin Proteins 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SK634-99A 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia SK63499A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9613969A FR2755975B1 (fr)	1996-11-15	1996-11-15	Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
PCT/FR1997/002043 WO1998022606A1 (fr)	1996-11-15	1997-11-13	Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (1)

Publication Number	Publication Date
SK63499A3 true SK63499A3 (en)	2000-05-16

Family

ID=9497670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK634-99A SK63499A3 (en)	1996-11-15	1997-11-13	Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Country Status (14)

Country	Link
EP (1)	EP0941355A1 (cs)
JP (1)	JP2001506488A (cs)
KR (1)	KR20000053320A (cs)
AU (1)	AU721654B2 (cs)
BR (1)	BR9712957A (cs)
CA (1)	CA2271437A1 (cs)
CZ (1)	CZ170399A3 (cs)
FR (1)	FR2755975B1 (cs)
HU (1)	HUP9904500A3 (cs)
IL (1)	IL129823A0 (cs)
NO (1)	NO992260D0 (cs)
SK (1)	SK63499A3 (cs)
WO (1)	WO1998022606A1 (cs)
ZA (1)	ZA9710271B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002506651A (ja) *	1998-03-16	2002-03-05	イントロジェン・セラピューティクス，インコーポレイテッド	多重遺伝子ベクター
AU7769800A (en) *	1999-08-10	2001-03-05	Develogen Ag Fur Entwicklungsbiologische Forschung	Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (fr) *	1999-10-07	2004-07-16	Aventis Pharma Sa	Preparation d'adenovirus recombinants et de banques adenovirales
WO2001073093A2 (en) *	2000-03-24	2001-10-04	Cell Genesys, Inc.	Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en)	2000-06-02	2003-04-08	Genphar, Inc.	Adenovirus vector with multiple expression cassettes
US7208322B2 (en)	2001-04-02	2007-04-24	Agilent Technologies, Inc.	Sensor surfaces for detecting analytes
CA2843556A1 (en) *	2011-08-08	2013-02-14	Aptalis Pharma Ltd.	Method for dissolution testing of solid compositions containing digestive enzymes
JP7316711B2 (ja)	2019-08-19	2023-07-28	ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド	脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE213779T1 (de) *	1991-08-07	2002-03-15	W French Anderson	Interne ribosom eintrittsstellen enthaltene retrovirale vektoren
GB9125896D0 (en) *	1991-12-05	1992-02-05	Almond Jeffrey W	Bicistronic viruses
FR2704556B1 (fr) *	1993-04-30	1995-07-13	Rhone Poulenc Rorer Sa	Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) *	1994-07-05	1996-10-04	Inst Nat Sante Rech Med	Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
DE69534166T2 (de) *	1994-10-28	2006-03-09	Trustees Of The University Of Pennsylvania	Rekombinanter adenovirus und methoden zu dessen verwendung
FR2731710B1 (fr) *	1995-03-14	1997-04-30	Rhone Poulenc Rorer Sa	Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

1996
- 1996-11-15 FR FR9613969A patent/FR2755975B1/fr not_active Expired - Fee Related
1997
- 1997-11-13 HU HU9904500A patent/HUP9904500A3/hu unknown
- 1997-11-13 CZ CZ991703A patent/CZ170399A3/cs unknown
- 1997-11-13 ZA ZA9710271A patent/ZA9710271B/xx unknown
- 1997-11-13 BR BR9712957-7A patent/BR9712957A/pt not_active Application Discontinuation
- 1997-11-13 EP EP97945922A patent/EP0941355A1/fr not_active Withdrawn
- 1997-11-13 WO PCT/FR1997/002043 patent/WO1998022606A1/fr not_active Ceased
- 1997-11-13 AU AU51252/98A patent/AU721654B2/en not_active Ceased
- 1997-11-13 SK SK634-99A patent/SK63499A3/sk unknown
- 1997-11-13 JP JP52326398A patent/JP2001506488A/ja active Pending
- 1997-11-13 IL IL12982397A patent/IL129823A0/xx unknown
- 1997-11-13 CA CA002271437A patent/CA2271437A1/fr not_active Abandoned
- 1997-11-13 KR KR1019990704322A patent/KR20000053320A/ko not_active Ceased
1999
- 1999-05-10 NO NO992260A patent/NO992260D0/no unknown

Also Published As

Publication number	Publication date
CA2271437A1 (fr)	1998-05-28
NO992260L (no)	1999-05-10
ZA9710271B (en)	1998-08-21
WO1998022606A1 (fr)	1998-05-28
KR20000053320A (ko)	2000-08-25
AU5125298A (en)	1998-06-10
IL129823A0 (en)	2000-02-29
CZ170399A3 (cs)	1999-08-11
BR9712957A (pt)	2000-02-01
FR2755975B1 (fr)	1999-05-07
JP2001506488A (ja)	2001-05-22
FR2755975A1 (fr)	1998-05-22
NO992260D0 (no)	1999-05-10
HUP9904500A3 (en)	2002-01-28
EP0941355A1 (fr)	1999-09-15
HUP9904500A2 (hu)	2000-05-28
AU721654B2 (en)	2000-07-13

Publication	Publication Date	Title
JP3672494B2 (ja)	2005-07-20	機能的ゲノム適用にライブラリーを使用される遺伝子機能に関する高度処理能力スクリーニング法
KR100403708B1 (ko)	2004-05-31	재조합아데노-수반바이러스(aav)제조방법및이의용도
US6911199B2 (en)	2005-06-28	Targeted adenovirus vectors for delivery of heterologous genes
JP2019520391A (ja)	2019-07-18	網膜変性を処置するためのｃｒｉｓｐｒ／ｃａｓ９ベースの組成物および方法
JP2021533795A (ja)	2021-12-09	アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法
JPH10507927A (ja)	1998-08-04	改良されたアデノウイルスおよびその使用法
WO2001018048A2 (en)	2001-03-15	Smooth muscle cell promoter and uses thereof
SK63499A3 (en)	2000-05-16	Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
JP2013526840A (ja)	2013-06-27	組み換えブチリルコリンエステラーゼおよびその切断型
AU770005B2 (en)	2004-02-12	Selective regulation of adenovirus production
SK124897A3 (en)	1998-02-04	Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
US20020144302A1 (en)	2002-10-03	Novel constructs and vectors for the targeted and inducible expression of genes
CA2323235A1 (en)	1999-11-04	Adenoviral vectors for treating disease
US20040101512A1 (en)	2004-05-27	Adenoviral vectors for treating disease
WO2001002540A2 (en)	2001-01-11	Adenoviral vectors for treating disease
US20130210898A1 (en)	2013-08-15	Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US20130164262A1 (en)	2013-06-27	Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same
MXPA99004301A (es)	2000-01-01	Adenovirus recombinantes bicistronicos para el tratamiento de patologias relacionadas a las dislipoproteinemias
Fox	1998	Clinical Applications of Gene Therapy: Cardiovascular Disease
Zhang	2012	Adenovirus-based gene therapy approaches for hemophilia B
Santa Maria	2014	Development of gene therapy to deliver the receptor-specific rhTRAIL DHER variant to induce apoptosis in activated Hepatic Stellate Cells for the treatment of Liver Fibrosis